Drug intelligence / Profile preview

indacaterol + mometasone furoate

Development stage: Phase 2
Lead developer: Novartis
Modality: Small Molecules
Administration: Inhalation

Overview

Indacaterol + mometasone furoate is a fixed-dose combination medication for the treatment of asthma in adults and adolescents twelve years of age and older who are not adequately controlled with inhaled corticosteroids and inhaled short-acting beta-2 agonists. Indacaterol acts as a long-acting beta-2 adrenergic receptor agonist (LABA) that produces bronchodilation, while mometasone furoate is a corticosteroid that reduces pulmonary inflammation. The medication is administered via oral inhalation using the Breezhaler device.

Brand names: Atectura BreezhalerBemrist Breezhaler
Other names: indacaterol/mometasoneindacaterol and mometasone

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on indacaterol + mometasone furoate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on indacaterol + mometasone furoate.

Explore the full profile